Insulet (PODD) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.96% |
| Dec 31, 2025 | 23.71% |
| Sep 30, 2025 | 49.14% |
| Jun 30, 2025 | 69.23% |
| Mar 31, 2025 | 44.46% |
| Dec 31, 2024 | 23.57% |
| Sep 30, 2024 | 27.84% |
| Jun 30, 2024 | 22.20% |
| Mar 31, 2024 | 65.89% |
| Dec 31, 2023 | 22.78% |
| Sep 30, 2023 | -17.31% |
| Jun 30, 2023 | 18.84% |
| Mar 31, 2023 | 14.41% |
| Dec 31, 2022 | 68.97% |
| Sep 30, 2022 | 29.97% |
| Jun 30, 2022 | 35.37% |
| Mar 31, 2022 | 18.77% |
| Dec 31, 2021 | 20.61% |
| Sep 30, 2021 | -37.97% |
| Jun 30, 2021 | -103.01% |
| Mar 31, 2021 | -23.44% |
| Dec 31, 2020 | 35.77% |
| Sep 30, 2020 | 23.26% |
| Jun 30, 2020 | -102.30% |
| Mar 31, 2020 | -8.90% |
| Dec 31, 2019 | -123.69% |
| Sep 30, 2019 | 69.39% |
| Jun 30, 2019 | 57.40% |
| Mar 31, 2019 | -14.33% |
| Dec 31, 2018 | 46.36% |
| Sep 30, 2018 | 118.33% |
| Jun 30, 2018 | -97.18% |
| Mar 31, 2018 | -57.18% |
| Dec 31, 2017 | 11.75% |
| Sep 30, 2017 | 30.51% |
| Jun 30, 2017 | 18.48% |
| Mar 31, 2017 | -34.99% |
| Dec 31, 2016 | 30.09% |
| Sep 30, 2016 | -20.89% |
| Jun 30, 2016 | 15.77% |
| Mar 31, 2016 | -4.91% |
| Dec 31, 2015 | -15.76% |
| Sep 30, 2015 | 19.42% |